Contraception
Volume 81, Issue 1 , Pages 79-85 , January 2010

A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom® formulations in Cameroonian women

  • Francois-Xavier Mbopi-Keou

      Affiliations

    • Laboratoire de Santé Hygiène Mobile, Ministry of Public Health and Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon
    • ,
  • Sylvie Trottier

      Affiliations

    • Infectious Diseases Research Centre and Faculty of Medicine, Université Laval, Centre Hospitalier Universitaire de Québec, Centre Hospitalier de l'Université Laval, Québec, Québec, Canada G1V 4G2
    • ,
  • Rabeea F. Omar

      Affiliations

    • Infectious Diseases Research Centre and Faculty of Medicine, Université Laval, Centre Hospitalier Universitaire de Québec, Centre Hospitalier de l'Université Laval, Québec, Québec, Canada G1V 4G2
    • ,
  • Ngoh N. Nkele

      Affiliations

    • Yaounde Gynaecologic-Obstetric and Pediatric Hospital, Yaoundé, Cameroon
    • ,
  • Séraphin Fokoua

      Affiliations

    • Yaounde Gynaecologic-Obstetric and Pediatric Hospital, Yaoundé, Cameroon
    • ,
  • Enow R. Mbu

      Affiliations

    • Gynaecology Department and Faculty of Medicine and Biomedical Sciences, Central Hospital, University of Yaoundé I, Yaoundé, Cameroon
    • ,
  • Marc-Christian Domingo

      Affiliations

    • Infectious Diseases Research Centre and Faculty of Medicine, Université Laval, Centre Hospitalier Universitaire de Québec, Centre Hospitalier de l'Université Laval, Québec, Québec, Canada G1V 4G2
    • ,
  • Jean-Francois Giguère

      Affiliations

    • Infectious Diseases Research Centre and Faculty of Medicine, Université Laval, Centre Hospitalier Universitaire de Québec, Centre Hospitalier de l'Université Laval, Québec, Québec, Canada G1V 4G2
    • ,
  • Jocelyne Piret

      Affiliations

    • Infectious Diseases Research Centre and Faculty of Medicine, Université Laval, Centre Hospitalier Universitaire de Québec, Centre Hospitalier de l'Université Laval, Québec, Québec, Canada G1V 4G2
    • ,
  • Anthony Mwatha

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, WA 98117, USA
    • ,
  • Benoît Mâsse

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, WA 98117, USA
    • ,
  • Michel G. Bergeron

      Affiliations

    • Infectious Diseases Research Centre and Faculty of Medicine, Université Laval, Centre Hospitalier Universitaire de Québec, Centre Hospitalier de l'Université Laval, Québec, Québec, Canada G1V 4G2
    • Corresponding Author InformationCorresponding author. Tel.: +1 418 654 2705; fax: +1 418 654 2715.

Received 20 April 2009 ,Revised 30 June 2009 ,Accepted 7 July 2009.

References 

  1. Balzarini J, Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet. 2007;369:787–797
  2. Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS ONE. 2008;3:e1474
  3. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1977–1987
  4. Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359:463–472
  5. Editorial Newer approaches to HIV prevention. Lancet. 2007;369:615
  6. Johnston R. Microbicides 2002: an update. AIDS Patient Care STDS. 2002;16:419–430
  7. Bentley ME, Fullem AM, Tolley EE, et al. Acceptability of a microbicide among women and their partners in a 4-country Phase I trial. Am J Public Health. 2004;94:1159–1164
  8. Joint United Nations Programme on HIV/AIDS (UNAIDS) . 2008 report on the global AIDS epidemic. Accessed on 1st of December 2008 at http://data.unaids.org/en/knowledgecentre/HIVdata/epidemiology/epidemiologyslidesauto.asp
  9. WHO . The world health report 2002. Reducing risks, promoting healthy life. www.who.int/whr/2002/en/2002;[Accessed October 2004]
  10. WHO . Global prevalence and incidence of selected curable sexually transmitted infections. Overview and estimates. Reference number: WHO/HIV_AIDS/2001.02. http://www.who.int/hiv/pub/sti/pub7/en/index.html2001;
  11. Mbopi-Keou FX, Ongolo-Zogo P, Angwafo F, Ndumbe PM, Belec L. High impact of mobile units for mass HIV testing in Africa. AIDS. 2007;21:1994–1996
  12. Bestman-Smith J, Piret J, Desormeaux A, Tremblay MJ, Omar RF, Bergeron MG. Sodium lauryl sulfate abrogates human immunodeficiency virus infectivity by affecting viral attachment. Antimicrob Agents Chemother. 2001;45:2229–2237
  13. Piret J, Gagne N, Perron S, et al. Thermoreversible gel as a candidate barrier to prevent the transmission of HIV-1 and Herpes simplex virus type 2. Sex Transm Dis. 2001;28:484–491
  14. Piret J, Roy S, Gagnon M, et al. Comparative study of mechanisms of Herpes simplex virus inactivation by sodium lauryl sulfate and n-lauroylsarcosine. Antimicrob Agents Chemother. 2002;46:2933–2942
  15. Roy S, Gourde P, Piret J, et al. Thermoreversible gel formulations containing sodium lauryl sulfate or n-lauroylsarcosine as potential topical microbicides against sexually transmitted diseases. Antimicrob Agents Chemother. 2001;45:1671–1681
  16. Piret J, Laforest G, Bussieres M, Bergeron MG. Subchronic (26- and 52-week) toxicity and irritation studies of a novel microbicidal gel formulation containing sodium lauryl sulfate in animal models. J Appl Toxicol. 2008;28:164–174
  17. Howett MK, Neely EB, Christensen ND, et al. A broad-spectrum microbicide with virucidal activity against sexually transmitted viruses. Antimicrob Agents Chemother. 1999;43:314–321
  18. Haineault C, Gourde P, Perron S, et al. Thermoreversible gel formulation containing sodium lauryl sulfate as a potential contraceptive device. Biol Reprod. 2003;69:687–694
  19. Trottier S, Omar RF, Desormeaux A, et al. Safety, tolerance and acceptability of the Invisible Condom and its vaginal applicator in healthy women and their male sexual partners. Contraception. 2007;76:117–125
  20. Omar RF, Trottier S, Brousseau G, Lamarre A, Alexandre G, Bergeron MG. Distribution of a vaginal gel (Invisible Condom) before, during and after simulated sexual intercourse and its persistence when delivered by two different vaginal applicators: a magnetic resonance imaging study. Contraception. 2008;77:447–455
  21. Mbopi-Keou F-X, Trottier S, Omar RF, et al. A randomized, double-blind, placebo-controlled safety and acceptability study of two Invisible Condom® formulations in women from Cameroon. Contraception. 2009;80:484–492
  22. Schwartz JL, Ballagh SA, Kwok C, et al. Fourteen-day safety and acceptability study of the universal placebo gel. Contraception. 2007;75:136–141
  23. Tien D, Schnaare RL, Kang F, et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses. 2005;21:845–853
  24. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol. 1991;29:297–301
  25. World Health Organization (WHO)/Contraceptive Research and Development Program (CONRAD). Manual for the standarisation of colposcopy for the evaluation of vaginal products, Update 2004.CONRAD/2004.1/WHO/RHR/04.02.
  26. McGroarty JA, Tomeczek L, Pond DG, Reid G, Bruce AW. Hydrogen peroxide production by Lactobacillus species: correlation with susceptibility to the spermicidal compound nonoxynol-9. J Infect Dis. 1992;165:1142–1144
  27. Richardson BA, Martin HL, Stevens CE, et al. Use of nonoxynol-9 and changes in vaginal lactobacilli. J Infect Dis. 1998;178:441–445
  28. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74:14–22
  29. Tabbara S, Saleh AD, Andersen WA, Barber SR, Taylor PT, Crum CP. The Bethesda classification for squamous intraepithelial lesions: histologic, cytologic, and viral correlates. Obstet Gynecol. 1992;79:338–346
  30. Joshi S, Dutta S, Bell B, et al. Documenting intermenstrual bleeding in a vaginal microbicide study: case reports and lessons learned. AIDS Res Hum Retroviruses. 2006;22:294–296
  31. Kilmarx PH, van de Wijgert JH, Chaikummao S, et al. Safety and acceptability of the candidate microbicide Carraguard in Thai women: findings from a Phase II clinical trial. J Acquir Immune Defic Syndr. 2006;43:327–334
  32. Mayer KH, Maslankowski LA, Gai F, et al. Safety and tolerability of Tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006;20:543–551
  33. Mayer KH, Peipert J, Fleming T, et al. Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin Infect Dis. 2001;32:476–482
  34. Gupta KM, Barnes SR, Tangaro RA, et al. Temperature and pH sensitive hydrogels: an approach towards smart semen-triggered vaginal microbicidal vehicles. J Pharm Sci. 2007;96:670–681
  35. Juhasz J, Pimienta C, Lenaerts V. Adhesion of poloxamer 407 formulations on dog ileal segments in vitro. Eur J Pharm Biopharm. 1991;37:262–265

PII: S0010-7824(09)00347-3

doi: 10.1016/j.contraception.2009.07.002

Contraception
Volume 81, Issue 1 , Pages 79-85 , January 2010

Article Tools